Q2 2026 saw 5% revenue growth to $13B, with the growth portfolio up 14% and ELIQUIS up 21%. Full-year guidance for revenue and EPS was raised, supported by strong product performance and a robust pipeline with multiple pivotal readouts and regulatory milestones ahead.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.